RAGAN ARRISON: Open Payments
NPI 1518581115 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,508 in 83 payments from 16 companies in 2025. Trend: 2023 $1,333 · 2024 $1,642 · 2025 $1,508
Food & beverage: $1,508
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 24 | $354 |
| AstraZeneca Pharmaceuticals LP | 17 | $306 |
| GENZYME CORPORATION | 10 | $142 |
| Mallinckrodt Hospital Products Inc. | 4 | $105 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $105 |
| Merck Sharp & Dohme LLC | 4 | $94 |
| Electromed, Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Actelion Pharmaceuticals US, Inc. | 2 | $55 |
| Insmed, Inc. | 2 | $51 |
Products named: TRELEGY ELLIPTA, DUPIXENT, NUCALA, FASENRA, ACTHAR, ZERBAXA, OFEV, AIRSUPRA.
Industry payments across AR — which companies pay providers there.
